AMAM - Ambrx Provides Ongoing Phase 1/2 APEX-01 Trial of ARX517 Safety and Efficacy Data

2023-10-16 09:09:21 ET

DENVER, Colo., Oct 16, 2023 ( www.247marketnews.com )- Ambrx Biopharma, Inc. (NASDAQ: AMAM) stated, this morning, that it published two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01 (NCT04662580), evaluating ARX517 for metastatic castration-resistant prostate cancer (mCRPC) and were made available as part of the 2023 European Society of Medical Oncology (ESMO) Congress 2023 meeting, taking place in Madrid, Spain, October 20-24, 2023.

Key updates from the newly published abstract include:

• ?50% PSA reduction observed across putative therapeutic dose levels ?2.0 mg/kg – 3 of 3 in Cohort 6 (2.0 mg/kg), 2 of 3 in Cohort 7 (2.4 mg/kg) and 2 of 3 in Cohort 8 (2.88 mg/kg)
• No drug-related severe adverse events (SAEs)

…

The post Ambrx Provides Ongoing Phase 1/2 APEX-01 Trial of ARX517 Safety and Efficacy Data appeared first on 24/7 Market News .

For further details see: